Citadel Advisors’s Adverum Biotechnologies ADVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-7,600
| Closed | -$33.2K | – | 12344 |
|
|
2025
Q1 | $33.2K | Sell |
7,600
-2,600
| -25% | -$11.7K | ﹤0.01% | 12719 |
|
|
2024
Q4 | $47.6K | Buy |
10,200
+4,200
| +70% | +$28.3K | ﹤0.01% | 12447 |
|
|
2024
Q3 | $42.1K | Buy |
6,000
+1,870
| +45% | +$13.6K | ﹤0.01% | 12096 |
|
|
2024
Q2 | $28.3K | Buy |
+4,130
| New | +$38.4K | ﹤0.01% | 12325 |
|
|
2024
Q1 | – | Sell |
-270
| Closed | -$2.03K | – | 14475 |
|
|
2023
Q4 | $2.03K | Buy |
270
+250
| +1,250% | +$2.28K | ﹤0.01% | 13750 |
|
|
2023
Q3 | $300 | Buy |
+20
| New | +$359 | ﹤0.01% | 14092 |
|
|
2023
Q1 | – | Sell |
-1,070
| Closed | -$6.2K | – | 14635 |
|
|
2022
Q4 | $6.2K | Hold |
1,070
| – | – | ﹤0.01% | 13935 |
|
|
2022
Q3 | $10K | Sell |
1,070
-40
| -4% | -$526 | ﹤0.01% | 12270 |
|
|
2022
Q2 | $13K | Sell |
1,110
-6,290
| -85% | -$65.9K | ﹤0.01% | 12519 |
|
|
2022
Q1 | $97K | Sell |
7,400
-23,950
| -76% | -$350K | ﹤0.01% | 12310 |
|
|
2021
Q4 | $552K | Buy |
31,350
+6,480
| +26% | +$130K | ﹤0.01% | 9454 |
|
|
2021
Q3 | $540K | Sell |
24,870
-36,330
| -59% | -$927K | ﹤0.01% | 9677 |
|
|
2021
Q2 | $2.14M | Sell |
61,200
-6,390
| -9% | -$344K | ﹤0.01% | 6431 |
|
|
2021
Q1 | $6.66M | Buy |
67,590
+15,820
| +31% | +$1.9M | ﹤0.01% | 3685 |
|
|
2020
Q4 | $5.61M | Buy |
51,770
+48,200
| +1,350% | +$5.96M | ﹤0.01% | 3500 |
|
|
2020
Q3 | $368K | Buy |
3,570
+2,370
| +198% | +$355K | ﹤0.01% | 7794 |
|
|
2020
Q2 | $251K | Buy |
1,200
+40
| +3% | +$7.08K | ﹤0.01% | 8203 |
|
|
2020
Q1 | $113K | Sell |
1,160
-90
| -7% | -$10.5K | ﹤0.01% | 8546 |
|
|
2019
Q4 | $144K | Sell |
1,250
-16,020
| -93% | -$1.41M | ﹤0.01% | 8387 |
|
|
2019
Q3 | $941K | Buy |
17,270
+16,000
| +1,260% | +$1.8M | ﹤0.01% | 5701 |
|
|
2019
Q2 | $151K | Buy |
+1,270
| New | +$105K | ﹤0.01% | 8351 |
|
|
2018
Q3 | – | Sell |
-1,650
| Closed | -$87K | – | 9146 |
|
|
2018
Q2 | $87K | Sell |
1,650
-150
| -8% | -$9.02K | ﹤0.01% | 8294 |
|
|
2018
Q1 | $104K | Buy |
+1,800
| New | +$112K | ﹤0.01% | 7694 |
|
|
2015
Q4 | – | Sell |
-1,160
| Closed | -$96K | – | 8669 |
|
|
2015
Q3 | $96K | Sell |
1,160
-2,130
| -65% | -$272K | ﹤0.01% | 6985 |
|
|
2015
Q2 | $534K | Buy |
3,290
+2,630
| +398% | +$887K | ﹤0.01% | 4855 |
|
|
2015
Q1 | $267K | Buy |
+660
| New | +$279K | ﹤0.01% | 5819 |
|
Citadel Advisors's ADVM Position: Q4 2025 in Review
Citadel Advisors sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 17,267 shares — an estimated $78.2K sold.
Citadel Advisors first reported a position in ADVM in Q3 2014 and held it in 35 quarters. The position peaked at $18M in Q2 2020. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.
- Citadel Advisors reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
- Citadel Advisors sold 17,267 Adverum Biotechnologies shares in Q4 2025, an estimated $78.2K.
- Citadel Advisors first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 35 quarters.
- Citadel Advisors's Adverum Biotechnologies position peaked at $18M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.
Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.